2022
Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer
Leapman MS, Dinan M, Pasha S, Long J, Washington SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncology 2022, 8: 687-696. PMID: 35238879, PMCID: PMC8895315, DOI: 10.1001/jamaoncol.2021.8116.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingPopulation-based cohort studyProstate cancerWhite patientsRacial disparitiesCohort studyMRI useIndividual-level socioeconomic statusEligible male patientsSocioeconomic statusNeighborhood-level socioeconomic statusLocalized prostate cancerProstate cancer diagnosisObserved racial disparitiesProstate magnetic resonanceMediation analysisPathologic factorsMale patientsUS SurveillanceBlack patientsMedicare databaseMAIN OUTCOMEUS adultsNew diagnosis
2021
Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations
Miller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation In Aging 2021, 5: 703-703. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaProportional hazards regressionOral anticancer agentsMRCC diagnosisCell carcinomaHazards regressionRisk factorsCox proportional hazards regressionOlder adultsNon-cancer controlsMild cognitive impairmentCohort entryRenal dysfunctionOnly patientsSurgical therapyWhite patientsBlack patientsSEER-MedicareDementia onsetMAIN OUTCOMEExclusion criteriaHigh riskPatientsCognitive impairmentPatient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patientsMediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areasReporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatients
2019
Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes
Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Stang MT, Roman SA, Sosa JA, Scheri RP. Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes. Surgery 2019, 166: 895-900. PMID: 31288935, PMCID: PMC6802283, DOI: 10.1016/j.surg.2019.05.035.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerLow-risk papillary thyroid cancerEmergency department visitsShort-term outcomesTotal thyroidectomyThyroid cancerFemale patientsBlack patientsEnd Results-Medicare databaseMore emergency department visitsLow-risk thyroid cancerExtent of thyroidectomyExtent of surgeryMultivariable logistic regressionUnderwent lobectomyUnplanned readmissionOlder patientsAvoidable complicationsMean ageMorbidity increasesThyroidectomyPatientsReadmissionComplicationsLobectomy
2018
Advanced imaging and hospice use in end-of-life cancer care
Dinan MA, Curtis LH, Setoguchi S, Cheung WY. Advanced imaging and hospice use in end-of-life cancer care. Supportive Care In Cancer 2018, 26: 3619-3625. PMID: 29728843, DOI: 10.1007/s00520-018-4223-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanBreast NeoplasmsColorectal NeoplasmsComorbidityDiagnostic ImagingFemaleHospice CareHospicesHumansLung NeoplasmsMaleMedicareMiddle AgedNeoplasmsOutcome Assessment, Health CareProstatic NeoplasmsReferral and ConsultationRetrospective StudiesSEER ProgramTerminal CareUnited StatesConceptsHospital referral regionsHospice enrollmentComputerized tomographyHospice useLife careReferral regionsAdvanced imagingPopulation-based retrospective studyHigh rateLate hospice enrollmentLife cancer careMultivariable logistic regressionSEER-Medicare dataMagnetic resonance imagingPositron emission tomographyEnd of lifeGreater comorbidityReal-world practiceAggressive endBlack patientsMultivariable analysisRetrospective studyResultsA totalStudy criteriaCancer care
2015
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanBreast NeoplasmsClinical Trials, Phase II as TopicConfounding Factors, EpidemiologicErbB ReceptorsFemaleGene Expression ProfilingHealthcare DisparitiesHumansInsurance CoverageLymphatic MetastasisMiddle AgedMolecular Targeted TherapyNeoplasm StagingNorth CarolinaPoisson DistributionPractice Guidelines as TopicPrecision MedicinePredictive Value of TestsResearch DesignRisk AssessmentRisk FactorsConceptsNode-positive breast cancerNon-black womenODX testingNode-negative patientsBreast cancerOncotype DXBlack patientsRacial disparitiesEarly-stage breast cancerCarolina Breast Cancer StudyGuideline-concordant careNode-positive patientsCancer care qualityPopulation-based studyOncotype DX testingQuality of careNorth Carolina womenLow socioeconomic statusMedium tumor sizeBlack womenBreast Cancer StudyAdjuvant chemotherapyMore comorbiditiesConcordant careTumor size